• About
  • Subscribe
  • Advertise
  • Contact
Thursday, December 5, 2024
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Company updates & acquisitions

Johnson & Johnson launching ACUVUE OASYS MAX 1-Day Sphere and Multifocal contact lenses

by Staff Writer
May 31, 2024
in Company updates & acquisitions, Contact lenses, Multifocal contact lenses, News
Reading Time: 6 mins read
A A
The ACUVUE OASYS MAX 1-Day spherical contact lens and ACUVUE OASYS MAX 1-Day MULTIFOCAL contact lens will be available to wearers in Australia from 1 July 2024. Image: Johnson&Johnson.

The ACUVUE OASYS MAX 1-Day spherical contact lens and ACUVUE OASYS MAX 1-Day MULTIFOCAL contact lens will be available to wearers in Australia from 1 July 2024. Image: Johnson&Johnson.

Share on FacebookShare on Twitter

Johnson & Johnson (J&J) is on the eve of launching its newest eye health innovation in Australia, ACUVUE OASYS MAX 1-Day spherical contact lens and ACUVUE OASYS MAX 1-Day MULTIFOCAL contact lens.

According to the company, the latest ACUVUE contact lenses have been designed with today’s modern lifestyles in mind. It is reported to offer a fresh, dynamic solution for those who enjoy the freedom to live life outside their frames while maximising their visual performance in all of life’s circumstances – at work, at play and in-between.

The lenses will be available to wearers in Australia from 1 July 2024.

“Through a deep innovation heritage in eyecare, Johnson & Johnson has seen how the needs of contact lens wearers have changed over time. In the age of digital technology and a persistent trend towards longer screen time, it is our role to continuously predict, adapt, and innovate to support our wearers’ needs,” said Ms Michelle Ho, business unit director at Johnson & Johnson Vision Australia and New Zealand.

“There’s a huge need for innovation like ACUVUE OASYS MAX 1-Day, that has been informed by wearers and eyecare professionals, priming it to keep up with the lifestyles of all Australians, and address eye strain as a result of longer days and increased time looking at digital devices.”

According to J&J, the lenses arrive at a pivotal time due to greater demands on people’s eyes. Between work and personal devices, adults spend an average of 13+ hours looking at screens daily,1 as the battle for attention and “the lure of the infinite scroll function” become a common feature of daily lives.

Through a combination of new technologies, ACUVUE OASYS MAX 1-Day lenses have been built for reliable comfort and performance.

J&J said its TearStable Technology maximises tear-film stability and locks in moisture for exceptional all-day comfort,2 while the OptiBlue light filter has the highest level blue-violet light filter in the industry at 60%‡,1 to help reduce light scatter and increase visual clarity, day and night. In addition, ACUVUE OASYS MAX 1-Day lenses block 99.9% UVA rays and 100% UVB rays,††,§§,3,4 

“As Australians continue to redefine what success and fulfillment means in this new digital intensive world, the ACUVUE OASYS MAX 1-Day features provide the assurance that their lenses will keep up with them, giving them the freedom and flexibility to pursue their ambitions, side hustles, hobbies, and new experiences, whatever they may be,” a company statement said.

For patients with presbyopia, J&J said ACUVUE OASYS MAX 1-Day Multifocal contact lenses provide crisp, clear vision at all distances and in all lighting conditions, as well as all-day comfort.5  The lenses combine the same two powerful technologies – TearStable Technology and the OptiBlue light filter – plus PUPIL OPTIMISED DESIGN technology, which tailors 100% of parameters to pupil size variations across both age and refraction compared to less than 2% for the leading competitor, for exceptionally effortless vision6 This is the same technology that is available across all ACUVUE Multifocal contact lenses.5

ACUVUE OASYS MAX 1-Day builds on the ACUVUE portfolio of products, which J&J said is unbeaten in comfort across 29 clinical studies.‡‡ In clinical trials of ACUVUE OASYS MAX 1-Day, nearly 90% of wearers reported all-day comfort and a reduction in tired eyes from digital devices, and nearly 100% agreed the lenses provided clear, reliable vision.2

For more information and to stay informed of product availability, visit https://au.jnjvisionpro.com/

More reading

Does your practice have a good contact lens culture?

How optometrists can cultivate positive contact lens culture

The power of dual contact lens and glasses wear

References

  1. Eyesafe estimate based upon Nielsen Q3 2019 Total Audience Report. https://eyesafe.com/covid-19-screen-time-spike-to-over-13-hours-per-day/
  2. JJV Data on File, 2022. CSM Subjective Responses ACUVUE OASYS MAX 1-Day Contact Lenses- Retrospective Meta-analysis.
  3. JJV Data on File 2022. Material Properties: 1-DAY ACUVUE MOIST, 1-DAY ACUVUE TruEye, ACUVUE OASYS 1-Day with HydraLuxe Technology and ACUVUE OASYS MAX 1-Day with TearStable Technology Brand Contact Lenses.
  4. JJV Data on File 2022: Master Brand Claims on Clinical Performance and Overall Material Properties for ACUVUE Brand Soft Contact Lenses.
  5. JJV Data on File 2022. Subjective Stand-Alone Claims for ACUVUE OASYS MAX 1-Day MULTIFOCAL Contact Lenses – Exploratory Meta-analysis.
  6. JJV Data on file 2022. CSM- ACUVUE PUPIL OPTIMIZED DESIGN Technology: JJVC contact lenses, design features, and associated benefits.

† Filtering of HEV light by contact lenses has not been demonstrated to confer any systemic and/or ocular health benefit to the user. The Eye Care Professional should be consulted for more information.

‡ Versus publicly available knowledge as of December 2023.

†† Helps protect against transmission of harmful UV radiation to the cornea & into the eye.

§§ WARNING: UV-absorbing contact lenses are the NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. You should continue to use UV-absorbing eyewear as directed. NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV-blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-blocking contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your eye care practitioner for more information.

§ Compared to competitor’s designs, technology optimized for both the parameters of refractive error and add power.​

‡‡ ClinicalTrials.gov is a website maintained by the NIH. The 29 clinical studies evaluated subjective comfort as a primary or secondary endpoint for ACUVUE OASYS Brand 2-week family, ACUVUE OASYS 1-Day Brand family, and ACUVUE OASYS MAX 1-Day Brand family of contact lenses, vs. competitors’ products. Review conducted as of April 2024.

Related Posts

Or lack of it, depending on where you live, is the concern of the CPMC and others. Image: BJP7images/stock.adobe.com.

Health ministers warned that fast-track changes could bring ‘postcode’ health care

by Staff Writer
December 5, 2024

Australia’s state health ministers have been warned that the proposed fast-track registration of Specialist International Medical Graduates (SIMGs) risks exacerbating...

Alcon has confirmed its new Unity systems are now registered in Australia, and will be commercially available in 2025. Image: Konektus Photo/Shutterstock.com.

All-new Alcon Unity vitreoretinal and cataract systems approved in Australia

by Myles Hume
December 4, 2024

Alcon has revealed its “highly anticipated” Unity Vitreoretinal Cataract System and Unity Cataract System have been included on the Australian...

Theo Charalambous (left) is the new president of Optometry Australia. Also getting new roles on the board are Shavu Bose, Ramy Aziz and Elise Pocknee-Clem. Image: Optometry Australia.

Changes at the top in Optometry Australia national board shuffle

by Staff Writer
December 3, 2024

Mr Theo Charalambous has been appointed president and Mr Shuva Bose as vice-president of Optometry Australia (OA). Charalambous succeeds Ms...

Join our newsletter

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited